NASDAQ: EGRX - Eagle Pharmaceuticals, Inc.

Rentabilidad a seis meses: -90.44%
Sector: Healthcare

Calendario de promoción Eagle Pharmaceuticals, Inc.

Horario avanzado gráfico sencillo
Financial Markets by TradingView

Acerca de la empresa

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.

más detalles
Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Añadir a la lista de comparación
Añadir a la lista de vigilancia
Añadir al portafolio
Añadir aviso de precio

IPO date 2014-02-12
ISIN US2697961082
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.eagleus.com
Цена ао 5.04
Cambio de precio por día: -2% (0.5102)
Cambio de precio por semana.: -9.09% (0.55)
Cambio de precio por mes: -29.58% (0.71)
Cambio de precio en 3 meses.: -87.34% (3.95)
Cambio de precio en seis meses: -90.44% (5.23)
Cambio de precio por año: -90.44% (5.23)
Cambio de precio en 3 años.: -99.1% (55.42)
Cambio de precio en 5 años.: -99.11% (56.22)
Cambio de precio en 10 años.: 0% (0.5)
Cambio de precio desde principios de año.: -35.06% (0.77)
Todos los parámetros

Subestimación

Nombre Significado Calificación
P/S 1.2 9
P/BV 1.63 8
P/E 10.67 9
EV/EBITDA 5.92 9
Total: 9

Eficiencia

Nombre Significado Calificación
ROA, % 10.8 4
ROE, % 17.39 5
Total: 4.33

Dividendos

Nombre Significado Calificación
Div yield, % 0 0
DSI 0 0
Total: 0.2257

Deber

Nombre Significado Calificación
Debt/EBITDA 0.9542 9
Total: 7.2

Impulso de crecimiento

Nombre Significado Calificación
Rentabilidad Revenue, % 48.43 6
Rentabilidad Ebitda, % 91.84 9
Rentabilidad EPS, % 30.52 5
Total: 4.4
Más detalles

Instituciones Volumen Compartir, %
Blackrock Inc. 984908 7.58
Janus Henderson Group PLC 775525 5.97
Brandes Investment Partners L.P. 745080 5.74
Vanguard Group Inc 638124 4.91
Millennium Management LLC 522402 4.02
AQR Capital Management, LLC 493665 3.8
LSV Asset Management 391758 3.02
Morgan Stanley 296864 2.29
Renaissance Technologies, LLC 294450 2.27
Acadian Asset Management. LLC 287555 2.21

ETF Compartir, % Rentabilidad del año, % Dividendos, %
Royce Quant Small‑Cap Quality Value ETF 0.19827 21.83 1.62596
Invesco FTSE RAFI US 1500 Small-Mid ETF 0.01366 17.58 1.75869
iShares Micro-Cap ETF 0.01037 17.09 1.54048
Schwab U.S. Small-Cap ETF 0.00121 17.47 1.51433



Supervisor Título profesional Pago año de nacimiento
Mr. Michael Graves Interim Principal Executive Officer & Executive Chairman of the Board 160k 1963 (62 año)
Dr. Valentin R. Curt M.D. Senior Vice President of Clinical Drug Development N/A
Dr. Gaozhong Zhu Ph.D. Senior Vice President of Pharmaceutical Development N/A
Mr. Reed McClung Executive Vice President of Oncology Business Development N/A
Mr. Steven B. Ratoff Interim CFO, Principal Accounting Officer & Director 100k 1943 (82 año)
Mr. Daniel O'Connor Executive VP, Chief Strategy Officer & Head of Corporate Development 1980 (45 años)
Ms. Debra Marie Hussain Senior VP & Head of Commercial 1968 (57 años)

DIRECCIÓN: United States, Woodcliff Lake. NJ, 50 Tice Boulevard - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://www.eagleus.com